[
  {
    "ts": null,
    "headline": "Stryker (SYK) Sees Higher Price Target from UBS amid Continued MedTech Strength",
    "summary": "Stryker Corporation (NYSE:SYK) is included among the 13 Best Performing Long Term Stocks to Invest in. On February 24, UBS raised its price recommendation on Stryker Corporation (NYSE:SYK) to $400 from $386. The firm kept a Neutral rating on the stock. During the Q4 2025 earnings call, CEO Kevin Lobo described 2025 as an outstanding year. […]",
    "url": "https://finnhub.io/api/news?id=39f64ca72032bae48fd90539d1c83a30fa4271893f74793f0d49b952e05b7b3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772331090,
      "headline": "Stryker (SYK) Sees Higher Price Target from UBS amid Continued MedTech Strength",
      "id": 139267593,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SYK",
      "source": "Yahoo",
      "summary": "Stryker Corporation (NYSE:SYK) is included among the 13 Best Performing Long Term Stocks to Invest in. On February 24, UBS raised its price recommendation on Stryker Corporation (NYSE:SYK) to $400 from $386. The firm kept a Neutral rating on the stock. During the Q4 2025 earnings call, CEO Kevin Lobo described 2025 as an outstanding year. […]",
      "url": "https://finnhub.io/api/news?id=39f64ca72032bae48fd90539d1c83a30fa4271893f74793f0d49b952e05b7b3f"
    }
  }
]